138 related articles for article (PubMed ID: 36773456)
21. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
22. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
23. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
25. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
26. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812
[TBL] [Abstract][Full Text] [Related]
27. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
28. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Li YJ; Wang Y; Wang YY
J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
[TBL] [Abstract][Full Text] [Related]
30. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway.
Zhang L; Zheng Y; Zeng L; Zhang F; Che D; Cao Z; Huang C; Xian L; Zhang X; Zhang H; Guo Z
Life Sci; 2021 Nov; 285():119995. PubMed ID: 34592228
[TBL] [Abstract][Full Text] [Related]
31. Betulin terpenoid targets OVCAR-3 human ovarian carcinoma cells by inducing mitochondrial mediated apoptosis, G2/M phase cell cycle arrest, inhibition of cell migration and invasion and modulating mTOR/PI3K/AKT signalling pathway.
Yang Q; Fei Z; Huang C
Cell Mol Biol (Noisy-le-grand); 2021 Sep; 67(2):14-19. PubMed ID: 34817343
[TBL] [Abstract][Full Text] [Related]
32. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
33. Novel sulfonyl-substituted tetrandrine derivatives for colon cancer treatment by inducing mitochondrial apoptosis and inhibiting PI3K/AKT/mTOR pathway.
Ling J; Li X; Wang M; Zhang C; Liu Y; Zhang X; Liu C; Ren Q; Zeng Y; Wang C; Chen Y; Sun C; Chen H; Zuo Y; Cao X; Deng Y; Ren B; Li D; Lu J
Bioorg Chem; 2024 Feb; 143():107069. PubMed ID: 38160477
[TBL] [Abstract][Full Text] [Related]
34. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K/Akt/mTOR/HIF-1α pathway.
Huang W; Ding X; Ye H; Wang J; Shao J; Huang T
Neuroreport; 2018 Dec; 29(18):1578-1585. PubMed ID: 30371540
[TBL] [Abstract][Full Text] [Related]
36. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
37. Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro.
Yang Y; Zhou X; Xiao M; Hong Z; Gong Q; Jiang L; Zhou J
J Huazhong Univ Sci Technolog Med Sci; 2010 Dec; 30(6):734-40. PubMed ID: 21181363
[TBL] [Abstract][Full Text] [Related]
38. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
39. Kaempferol inhibits proliferation, migration, and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21.
Zhu G; Liu X; Li H; Yan Y; Hong X; Lin Z
Int J Immunopathol Pharmacol; 2018; 32():2058738418814341. PubMed ID: 30477356
[TBL] [Abstract][Full Text] [Related]
40. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
Liu C; Pei J; Mu X; Yu B; Gong T; Liang W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):425-431. PubMed ID: 35603651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
